DiaMedica Therapeutics Inc. (DMAC) Covered Calls

You can sell covered calls on DiaMedica Therapeutics Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for DMAC (prices last updated Fri 4:16 PM ET):

DiaMedica Therapeutics Inc. (DMAC) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.57 +0.04 2.46 2.59 8K - 0.1
Covered Calls For DiaMedica Therapeutics Inc. (DMAC)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
May 17 2.5 0.15 2.44 2.5% 41.5%
Jun 21 2.5 0.00 2.59 -3.5% -22.4%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company also develops DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was founded in 2000 and is headquartered in Minneapolis, Minnesota.